BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sapena V, Enea M, Torres F, Celsa C, Rios J, Rizzo GEM, Nahon P, Mariño Z, Tateishi R, Minami T, Sangiovanni A, Forns X, Toyoda H, Brillanti S, Conti F, Degasperi E, Yu ML, Tsai PC, Jean K, El Kassas M, Shousha HI, Omar A, Zavaglia C, Nagata H, Nakagawa M, Asahina Y, Singal AG, Murphy C, Kohla M, Masetti C, Dufour JF, Merchante N, Cavalletto L, Chemello LL, Pol S, Crespo J, Calleja JL, Villani R, Serviddio G, Zanetto A, Shalaby S, Russo FP, Bielen R, Trevisani F, Cammà C, Bruix J, Cabibbo G, Reig M. Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. Gut 2021:gutjnl-2020-323663. [PMID: 33741640 DOI: 10.1136/gutjnl-2020-323663] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Trevisani F, Giannini EG; Italian Liver Cancer (ITA.LI.CA) group. The ITA.LI.CA Consortium: How multicentre collaboration helped shape the management of patients with hepatocellular carcinoma on the basis of real-world evidence. Ann Hepatol 2021;:100564. [PMID: 34688886 DOI: 10.1016/j.aohep.2021.100564] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Reig M, Cabibbo G. Antiviral therapy in the palliative setting of HCC (BCLC-B and -C). J Hepatol 2021;74:1225-33. [PMID: 33582128 DOI: 10.1016/j.jhep.2021.01.046] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
3 Hernaez R, Thimme R. End of the story: direct-acting antiviral agents are not associated with recurrence of hepatocellular carcinoma. Gut 2021:gutjnl-2021-324288. [PMID: 33785552 DOI: 10.1136/gutjnl-2021-324288] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Choi WM, Yip TC, Lim YS, Wong GL, Kim WR. Methodological challenges of performing meta-analyses to compare the risk of hepatocellular carcinoma between chronic hepatitis B treatments. J Hepatol 2021:S0168-8278(21)02079-1. [PMID: 34592365 DOI: 10.1016/j.jhep.2021.09.017] [Reference Citation Analysis]
5 D'Ambrosio R, Degasperi E, Lampertico P. Predicting Hepatocellular Carcinoma Risk in Patients with Chronic HCV Infection and a Sustained Virological Response to Direct-Acting Antivirals. J Hepatocell Carcinoma 2021;8:713-39. [PMID: 34235108 DOI: 10.2147/JHC.S292139] [Reference Citation Analysis]
6 Cannella R, Vernuccio F, Celsa C, Cabibbo G, Calvaruso V, Greco S, Battaglia S, Choudhury KR, Tang A, Midiri M, Di Marco V, Cammà C, Brancatelli G. Long-term evolution of LI-RADS observations in HCV-related cirrhosis treated with direct-acting antivirals. Liver Int 2021;41:2179-88. [PMID: 33908147 DOI: 10.1111/liv.14914] [Reference Citation Analysis]
7 Fouad M, El Kassas M, Ahmed E, El Sheemy R. Tumor characteristics of hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C: Comparative analysis with antiviral therapy-naive patients. World J Hepatol 2021; 13(11): 1743-1752 [PMID: 34904042 DOI: 10.4254/wjh.v13.i11.1743] [Reference Citation Analysis]
8 Vitale A, Svegliati-Baroni G, Ortolani A, Cucco M, Dalla Riva GV, Giannini EG, Piscaglia F, Rapaccini G, Di Marco M, Caturelli E, Zoli M, Sacco R, Cabibbo G, Marra F, Mega A, Morisco F, Gasbarrini A, Foschi FG, Missale G, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Oliveri F, Pelizzaro F, Ramirez Morales R, Cillo U, Trevisani F, Miele L, Marchesini G, Farinati F; Italian Liver Cancer (ITA.LI.CA) group. Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database. Gut 2021:gutjnl-2021-324915. [PMID: 34933916 DOI: 10.1136/gutjnl-2021-324915] [Reference Citation Analysis]
9 Ng A. Hepatocellular carcinoma recurrence after directly-acting antiviral therapy: caution with hepatitis C. European Journal of Gastroenterology & Hepatology 2021;33:e1091-2. [DOI: 10.1097/meg.0000000000002193] [Reference Citation Analysis]
10 Ezzat R, Eltabbakh M, El Kassas M. Unique situation of hepatocellular carcinoma in Egypt: A review of epidemiology and control measures. World J Gastrointest Oncol 2021; 13(12): 1919-1938 [DOI: 10.4251/wjgo.v13.i12.1919] [Reference Citation Analysis]
11 Badami E, Carcione C, Chinnici CM, Tinnirello R, Conaldi PG, Iannolo G. HCV Interplay With Mir34a: Implications in Hepatocellular Carcinoma. Front Oncol 2022;11:803278. [DOI: 10.3389/fonc.2021.803278] [Reference Citation Analysis]